caixa empreender award | cotec ebook (supporting doc)
TRANSCRIPT
!"#$%&$'()*'$+,-./"#0$!"#$%#!$%&'
• '()*+,*-.,/0'• '1,+2,3045'
• '60)78-'• '9:0;,);'• '<:)/3)'"='
• '>3,?-!@;,*,?'
• '@)4);A);+/'• '@!@'• 'B54/03+@:03'
• '@/C-4);60*-0'6+;DE+*-'
PROBLEM AND MARKET
50 million Chronic Wound patients worldwide
Up to 70% do not respond to conventional treatment
SOLUTIONUmbilical Cord Blood-derived Gel for Topic Administration
NANOSCALE THERAPEUTIC SOLUTIONS FOR
REGENERATIVE MEDICINE
TEAMFINANCIAL NEEDS
Pre-clinical Development: 2.5M
Phase 1-2 Clinical Trial: 5M
Phase 3 Clinical Trial: 19M
BioMimetx is a newborn global biotech start-up focused on the development of "green" antifouling solutions, to prevent marine biofouling. The financial impact of biofouling on maritime operations can reach an increase of !51 billions in fuel acquisition expenses and an additional !3,7 billions in maintenance costs for the world fleet per year. "BioMimetx discovered and owns environmental bacteria that secrete high levels of molecules, which can be used as natural antimicrobials and algaecides. Straightforward to produce, cost e#ective, non-toxic and with a broad-range e#ectiveness, the product of BioMimetix is translated as an innovative solution by a committed and resilient team of science specialists and a management expert. Our addressable market, is the global market of biocide additives for marine paints that was estimated in !2.5 Billion for 2014. BioMimetx, will enter this market through the USA then expanding to the rest of the world. Sales will begin in year 4 with an EBITDA of !11 Millions three years after market entry. For this, we will require !1,4 Millions, having already granted 400 K ! from a venture capital company and a private investor. ""
We are developing a first-in-class analgesic from marine origin that modulates a key therapeutic target (ion channel) away from the brain, stopping pain perception.
Marine library generation Bioactive compound characterization Patent I Synthesis of 1st lead molecule Patent II Pre-clinical studies Investigational New Drug Application
NEXT STEP DELIVERABLES
913K (3 years) to finish pre-clinical studies
EXIT OPTION
TOTAL INVESTMENT
!"#$%&$'()*'+++,)-%.(),/$'0'1#2"3)-%.(),/$'0'4567'895:;<6<7'
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"# $# "#$%&'(! )%*+%,-.!%&'(")*# &+# /#)'$0&+1! *2/! /&0&3$.4&2%! &%#2$0&3!.(*+4*'&-%#'*3),#-$")*#&+#'&.)#)/0).1!")#!+##$2!'(*22&3)#$+*#4*+#2&!"#$3$512##
!6&*78)#
!"#$%&$'''(#)*'+#(#,&*%-('./('0&,#'
!"#$%&$!" #$%&'()"*'+,-./"0&121"" (&'+,-./34&56$'61%.+"" 77714&56$'61%.+"
89$/"$-"4&5"+.-4"%.++./"%'/%5("-$451":;"$/"-</"6$=&4"$-"'"+'>.("%'<-5".?"-9$/"%'/%5(1"@<((5/4"-</"%'(5"(56$5-"./":;",(.45%4$./"'6./51"A&56$'6"$-"</$B<5"$/"'))$/="'%4$C5"%'/%5(",(.,&D6'E$-"4."-</"%'(51"
!
!"#$%&'(#)*%++,-.)"#$%&$'(!)*+*!,-!$!".%/0102-2!-/$%/304!5$-26!,7!8,-5.7!626,9$/26!/.!/#2!62:2;.4&27/<!4%.609/,.7!$76!9.&&2%9,$;,=$/,.7!.>!$!72?!1272%$/,.7!.>!27#$7926!42%>.%&$792!@ABC-! D@,1#!A079/,.7$;,/E!BF9,4,27/-G*!BF9,4,27/-!$%2! ,7$9/,:2! ,71%26,27/-!0-26!/.!>.%&0;$/2!$9/,:2! ,71%26,27/-! ,7/.!>,7,-#26!6.-$12!>.%&-*!+!9.&&.7!6%01! ,-!9.&4.-26!.>!$9/,:2!4#$%&$920/,9$;!,71%26,27/-<!/#2!$9/0$;!/#2%$420/,9!$127/!$76!2F9,4,27/-*!
"#$%&$'(!#$-!62:2;.426!$! /29#7.;.1E!4;$/>.%&!9$4$5;2!.>!62;,:2%,71!5,.9.&4.-,/2-<!?,/#!#,1#3>079/,.7$;,/E!4%.42%/,2-!9$4$5;2!.>!$66%2--,71!/#2!42%>.%&$792!7226-!.>!6%01!>.%&0;$/.%-!.>!/#2!HHI!J27/0%E*!K#2!9.&4$7EC-!27/%E!,7!/#2!&$%L2/<!2F429/26! /.!.990%! ,7!M!E2$%-<!?,;;!#$4427!?,/#! /#2! ,7/%.609/,.7!.>!@"BN<!$! -.;,6!6.-$12!2F9,4,27/*!K#2!4%.609/!?,;;!52!27/2%,71!/#2!;$%12-/!2F9,4,27/C-!&$%L2/!-21&27/<!/#2!O,762%-!P!A,;;2%-*!
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
"#$%&$'(! ,-! 90%%27/;E! 0762%1.,71! /#2! -9$;2304! 4%.92--! $76! BF9,4,27/! "#$%&$9.42,$! +44%.:$;! >.%! /#2! ,760-/%,$;!4%.609/,.7!.>!,/-!>,%-/!2F9,427/<!@"BN*K#2!&$,7!$9/,:,/,2-!0762%!?$E!$%2U!
• )9$;2304!/.!VRR!8!.>!/#2!>2%&27/$/,.7!4%.92--!/.!4%.6092!/#2!5,.9.&4.-,/2!4.;E&2%!/#$/!,-!/#2!5$-,-!.>!/#2!@"BN!2F9,4,27/*!• A,72!/07,71!.>!@"BN!2F9,4,27/!• @"BN!BF9,4,27/!92%/,>,9$/,.7!0762%!AW+!$76!BX+!• "%2-27/$/,.7! $76! 62&.7-/%$/,.7! /.! /#2! "#$%&$920/,9$;! )9,27/,>,9! 9.&&07,/E! .>! /#2! 4%.609/-! 42%>.%&$792!$6:$7/$12-*!!
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
!"#$%#&'()(*!+(,(-".(+/0121.345(4"#4(6177(89954(4".(:3;<54$=(89449%(713.!
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
!"#$#%&"'67".#48*"'".
648 8)@),56)8%19:;<2=C%+;)%/"0#- <,558%<.0)8%%##%>/5(%.*%$%0*>&%'!&%..?0%-$&!"%,'(#"#&(/&12@"KLMN#= 40%'$A&,$'$0%-"('&5/%4*%@4+(5%84.A*50+4&%+)0+0%<.0)8%5*%.(7+"'%-"('&(/&#B$."/".&+"(7%0C$0#&8)+)&+)8%74+;%&'++4*A%)8A)%+)&;*5,5A-9%10(B0"$-%0>&!$)$*(B$!&%*,(0"-D7&&A4@)0%#.(0$ 7;4&;%'*)O'4@5&.,,-%84.A*50)%.*8%0+.A)%".(D4*05*%840).0)9
HPBE0%!"#$%&'(C%/%."*"-%-$&-D$0%B>&!$."#"('&.*8%6.+4)*+0%&.*%0+.(+%+().+3)*+%)+ ).(,-%5*0)+%5/%"#9%Q@)*%358)0+%8),.-%5/%6(5A()0045*%8(.0+4&.,,-%436(5@)%6.+4)*+0%7),,<)4*AC%3.4*+.4*%,4/)%O'.,4+- .*8%#%)$&7"**"('#& )@)(-%-).(9%R*+)A(.+)8%4*%&533'*4+-%.0%.*%0&())*4*A%+)0+%"KLMN#=;),60%6;-04&4.*0C%6.+4)*+0C%6;.(3.&)'+4&.,%4*8'0+(-%.*8%05&4)+-%<-%()8'&4*A%&50+0%5/%+().+3)*+9 534&0P&,4*4&S5'+,55D9&53
CATALVALOR
! !"#"$%"$&'( )*+*,-.*)( /( 0-,1)( 2/3/,403( 567!"#8( 39/3( /,,-:0( ;1-)1*0*,( .<-)=2>-?(@<-A(5=,3</8(,-:7B</)*(@**)03-2C0D((
! &=<(0-,=>-?(0-,+*0(39*(A/1?(.<-;,*A0(-@(;1-)1*0*,(.<-)=2>-?(0.*21/,,4(39*1<(,/2C(-@(2-A.*>>+*?*00( :9*?( 2-A./<*)( :139( .*3<-,*=A( ;/0*)( @=*,0D( #910( :*/C(2-A.*>>+*?*00(10(A/1?,4()=*(3-(39*(91B9(@**)03-2C(.<12*0( (5<*.<*0*?30(=.(3-(EF(G(-@(39*(-.*</>-?(2-0308(/?)(39*(;1-)1*0*,(.<-)=2>-?(.<-2*00(2-A.,*H134D(
! "23=/,,4( 39*( =0*( -@( ,-:7B</)*( @**)03-2C0( 10( 0>,,( /( .<-;,*A( @-<( 39*( 2-?+*?>-?/,(3*29?-,-B1*0( 01?2*( 1?+-,+*0( ( 0*+*</,( .<*7( 3<*/3A*?3( /?)( .-037( .=<1I2/>-?( 03*.0J(:9129(1?2<*/0*(39*(-+*</,,(.<-2*00(2-030D(
! !"#"$%"$&'(0-,=>-?(/,,-:0(39*(.<-)=2>-?(-@(91B9(K=/,134(;1-)1*0*,(@<-A(,-:(2-03(5=,3</87,-:( B</)*( @**)03-2C0J( 2-A;1?1?B( /( <*=0/;,*( 0-,1)( 2/3/,403(:139( /( 01A.,1I*)(.<-2*00(5EE(G(1?(-?*(03*.(<*/2>-?8(<*)=21?B(01B?1I2/?3,4(39*(&LM6(/?)(!"LM6(/?)(1?2<*/01?B(39*(2-A.*>>+*?*00(-@(39*(;1-)1*0*,(.<-)=2>-?D(
High performance battery for motive power applications !
CHARGE2CHANGE !"#$%&'()%
Nearly 99% of electric vehicles are powered by lead-acid batteries that suffer from long recharge time, short cycling life, no opportunity charges and environmental issues.
Charge2Change offers a lead free battery that features: 5x more life cycle, charges 10x
faster and accepts opportunity charges. The first target in this market will be electric forklifts,
that will benefit from no second battery expense, no battery handling equipment, no operator
downtime due to battery changes and no safety concerns during handling. Wrapping all the benefits together, with our offer the total annual costs of ownership can be at least cut in half
comparing to our competitors.!
*"'+)%
!"#$%&'()%
CHARGE2CHANGE
Longer life cycleShort charging timeOpportunity charge
Total ownership cost cut to half
Initial Funding
ENTRY MARKET
18
New material for energy storage
3D structure
High specific area
• High charging speed
TECHNOLOGY
Europe USA Brazil Japan South Korea
High specific area - High charging speed
Innovative approach to Electroplating
Single-step production
Low-cost process
Lead-free
André Mão de Ferro Sónia Eugénio Rui Pedro Silva
Research
Fátima Montemor (IST)
Maria João Carmezim (IPS)
Maria Teresa Silva (ISEL)
IndustryAna Gonçalves (Ex-Hovione)
José Pereira (Ex-Autosil)
Advisory Board
NEW GENERATION BATTERY
!"#$%"&'
()*+,-"./,-'!"#$%&'()*)&+,-.&/0)&#-!#%1$()'+/')('/2.0.(,)2.#!+/"-/&,%3&/0(4)
• 5,(()".(6()• 7/.1'/.1),8&/&9)• :.;+,")(/<,'9)• 5,(()0#((,()• 5,(()&#('()
0+"1#,-'
23"4/5+-56,$%65#7'=,>?)@/&&.1,(A4)• ):.;+)@/0%,)!"#$%&'()• )B"/1(!#"',$C('#",$)%(.1;)�$)&+/.1)/')D)*)E)#F)'#)!",(,"@,),8&/&9)/1$)(/<,'9)• )GH)0#((,()$%,)'#)</.0%",)#<)�$)&+/.1).1)I%"#!,)/1$)'+,)JKL)• )M1)$,@,0#!.1;)&#%1'".,(N).--/'%",)#").1,>.(',1')�$)&+/.1)0,/$()'#)+.;+,")0#((,()
O.'/)P,1'%"/N)".'/?@,1'%"/Q,>'",-#&+,-?&#-)I@/)5#%",1R#N),@/?0#%",1&#Q,>'",-#&+,-?&#-)
F+".('#!+,")7/9&#&6N)&+".(?-/9&#&6Q,>'",-#&+,-?&#-)
0#58"+-'9,6/&"#":;'
! K'/2.0.(/3#1)$%".1;)'+,)$#S1('",/-)!"#&,(()#<)+.;+)@/0%,)!"#',.1()/;/.1(')/;;",;/3#1)
! L$$.3@,)<#")(!"/9T)/1$)<",,U,T)$"9.1;)! V#"-%0/3#1()<#")-.&"#/""/9(N).--%1#/((/9(N)
2.#(,1(#"()! F#1'"#0)/1$)'",/'-,1')#<)WX)=,>?)L0U+,.-,"N)
Y/"6.1(#1A)! L$$.3@,)<#")(6.1)&/",)&",/-()
I>'",-#F+,-).()/)('/"'T%!)&#-!/19)
$,@#',$)'#)'+,)$,@,0#!-,1')/1$)&#--,"&./0.(/3#1)#<)&+,-.&/009)(91'+,(.(,$)
1#@,0),>&.!.,1'()<#")'+,)('/2.0.(/3#1)#<)
2.#0#;.&(?)
In 2014, 152 million tons of vegetable oil were consumed globally. Vegetable oils
originate from different oilseed sources (e.g. sunflower, soybean or palm) which are
produced worldwide. The vegetable oil is commonly obtained by solvent extraction with
hexane, a organic solvent derived from petroleum. However, this represents a major
problem for the consumers and producer industries because the presence of hexane
can compromise the oil quality and accounts for high costs of production. Currently,
hexane detection is performed by Gas Chromatography (GC), a very demanding
technique regarding operational costs, time, and specialized personnel.
The CrystalSense Solutions team proposes a portable and affordable device for a
rapid in situ hexane detection. Our product allows to decrease the time of analysis
and operational costs.
Team: Cecília Roque, Ana Sofia Pina and Margarida Dias
Hexane detection made easy